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Structural foundation for the design of receptor antagonists
targeting Escherichia coli heat-labile enterotoxin
Ethan A Merritt1, Steve Sarfaty2, Ingeborg K Feil2 and Wim GJ Hol1,2*
Background: Escherichia coli heat-labile enterotoxin (LT) is the causative
agent of traveller’s diarrhoea, and it is also responsible for the deaths of
hundreds of thousands of children per year in developing countries. LT is highly
homologous in sequence, structure and function to cholera toxin (CT). Both
toxins attack intestinal epithelial cells via specific binding to the branched
pentasaccharide of ganglioside GM1 at the cell surface. A receptor-binding
antagonist which blocked this interaction would potentially constitute a
prophylactic drug conferring protection both against the severe effects of
cholera itself and against the milder but more common disease caused by LT. 
Results: Four derivatives of the simple sugar galactose, members of a larger
series of receptor antagonists identified by computer modeling and competitive
binding studies, have been co-crystallized with either the full LT AB5 holotoxin
or the LT B pentamer. These crystal structures have provided detailed views of
the toxin in complex with each of the four antagonists: melibionic acid at 2.8 Å
resolution, lactulose at 2.65 Å resolution, metanitrophenylgalactoside (MNPG)
at 2.2 Å resolution and thiodigalactoside (TDG) at 1.7 Å resolution. The binding
mode of each galactose derivative was observed 5–15 times, depending on the
number of crystallographically independent toxin B pentamers per asymmetric
unit. There is a remarkable consistency, with one important exception, in the
location and hydrogen-bonding involvement of well-ordered water molecules at
the receptor-binding site.
Conclusions: The bound conformations of these receptor antagonist
compounds preserve the toxin–galactose interactions previously observed for
toxin–sugar complexes, but gain additional favorable interactions. The highest
affinity compound, MNPG, is notable in that it displaces a water molecule that is
observed to be well-ordered in all other previous and current crystal structures
of toxin–sugar complexes. This could be a favorable entropic factor contributing
to the increased affinity. The highest affinity members of the present set of
antagonists (MNPG and TDG) bury roughly half (400 Å2) of the binding-site
surface covered by the full receptor GM1 pentasaccharide, despite being
considerably smaller. This provides an encouraging basis for the creation of
subsequent generations of derived compounds that can compete effectively
with the natural receptor.
Introduction
Escherichia coli heat-labile enterotoxin, a close relative of
cholera toxin, is a secreted toxin that attacks epithelial
cells lining the intestine. The resulting disruption of
normal fluid balance leads to acute diarrhoea and
dehydration. The disease induced by E. coli is milder
than the severe diarrhoeal disease resulting from infec-
tion by Vibrio cholerae. Patients in either case can be
treated using oral rehydration therapy; however, even
this relatively simple therapy requires access to compe-
tent care and large amounts of potable water. Where
access is lacking, particularly in underdeveloped regions
of the world, the E. coli and V. cholerae toxins are jointly
responsible for millions of deaths annually [1]. Mortality
rates are highest in infants and children. The disease
organisms are spread through contaminated water sup-
plies, a process greatly exacerbated by the symptomatic
diarrhoea. An inexpensive and effective prophylactic
drug could therefore serve to prevent the spread of the
disease and reduce the likelihood and impact of out-
breaks. Moreover, such a drug could be useful in the pre-
vention of traveller’s diarrhoea, which is often caused by
enterotoxigenic E. coli.
The E. coli and V. cholerae toxins are 80% identical in the
amino acid sequence of both their catalytic A subunits
Addresses:  1Department of Biological Structure,
University of Washington, Seattle WA 98195-7742
and 2Howard Hughes Medical Institute, University
of Washington, Seattle WA 98195-7742.
*Corresponding author.
E-mail:  hol@xray.bchem.washington.edu
Key words: cholera toxin, crystal structure, drug
design
Received:  18 August 1997
Revisions requested:  9 September 1997
Revisions received:  3 October 1997
Accepted:  10 October 1997
Structure  15 November 1997, 5:1485–1499
http://biomednet.com/elecref/0969212600501485
© Current Biology Ltd ISSN 0969-2126
Research Article 1485
and their receptor-binding B subunits. They assemble as
AB5 hexamers and to a first approximation exhibit the
same three-dimensional tertiary structure. Antibodies to
the toxins are cross-reactive. Five identical receptor-
binding sites on the toxins’ B pentamer are highly spe-
cific for the characteristic oligosaccharide of ganglioside
GM1, although heat-labile enterotoxin additionally exhibits
minor affinity for other related gangliosides and possibly
also for galactoproteins [2]. It is likely that prophylactic
agents effective against one toxin will also be effective
against the other.
Decades of research on the genetics, expression, assem-
bly, secretion, receptor specificity, cellular uptake and
catalytic activity of these toxins have provided a wealth
of information that can be mined for the design of poten-
tial prophylactic drugs [3]. One particularly rich lode of
information is the atomic resolution view of the toxins’
molecular structure, gained from a series of crystal struc-
tures encompassing the wild-type toxins [4–8], a variety
of mutant toxins [9–12] and complexes of the toxins with
receptor fragments [12–16]. Several potential targets for
structure-based drug design have been illuminated by
this work, including the catalytic site on the A subunit,
the receptor-binding sites on the B pentamer, and the
unusual ‘string through a doughnut’ architecture of the
AB5 hexamer (Figure 1). Although we are actively pursu-
ing all three of these lines of attack, by far the most struc-
tural information is available for the receptor-binding site
and it is toward this target we have progressed the far-
thest, with key crystallographic results described in the
present paper.
We report here initial work on the design of receptor-
binding inhibitors, based on derivatives of the simple
sugar galactose. Galactose (β-D-galactopyranose) is the
terminal sugar of the branched pentasaccharide charac-
teristic of the natural receptor, ganglioside GM1, and is
deeply inserted into a cleft on the toxin upon receptor
binding. This work is motivated by a series of crystal
structures in which galactose-containing fragments of the
natural receptor are observed bound to the toxin [12–16].
In each of these previously determined crystal structures
the toxin–galactose interaction is characterized both by
hydrophobic stacking of the sugar ring against the indole
ring of Trp88 and by an extensive and highly conserved
network of direct and solvent-mediated hydrogen-bonding
interactions. The terminal galactose moiety of the GM1
pentasaccharide accounts for 38% (134 Å2) of the saccha-
ride’s total binding surface, as seen in the complex between
the cholera toxin B pentamer (CTB) and the GM1 oligo-
saccharide [12,15]. Similarly, 156 Å2 of the accessible
surface of the protein at each receptor-binding site in LT
is buried when the simple sugar galactose binds [14]. The
residues comprising the galactose-binding site on the
toxin are strictly conserved among all sequences reported
for isolates of both LT and CT, with a single exception
(His/Arg13) discussed later. The significant role played by
the galactose moiety of GM1 is also evident from the
reduction in affinity for the toxin if the terminal galactose
is not present; for CT, the IC50 measured via competitive
ELISA increases from 25 nM to 410 nM in the absence of
the terminal galactose [17].
The observations just summarized suggested that galac-
tose is well-suited as a starting point for the iterative
structure-based design of antagonists for toxin–receptor
binding. Furthermore, the nearly perfect structural homol-
ogy of the galactose-binding site in LT and CT allows us
to target both toxins simultaneously. An initial round of
directed screening based on database searches and com-
puter modeling identified a set of candidate galactose
derivatives (C Verlinde and W Minke, personal commu-
nication) with better inhibition of toxin–receptor bind-
ing than galactose itself. We subsequently determined
crystal structures for four of these compounds bound
either to the LT AB5 holotoxin or to the LT B pentamer.
This set of structures suggests obvious directions for the
subsequent design of a second generation of receptor
antagonists and also suggests improvements to the mod-
eling algorithms used to guide the choice of candidate
receptor antagonists.
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Figure 1
Toxin binding to cell surface. E. coli heat-labile enterotoxin is an AB5
heterohexamer. The five identical B subunits form a regular pentamer
with a central pore. The A subunit is cleaved during toxin activation into
two polypeptide chains A1 and A2. A1 contains the catalytic site; it is
tethered to the B pentamer by the extended C-terminal tail of A2,
which extends through the central pore and out the other side [5]. Five
receptor-binding sites on the B pentamer mediate specific binding to
the branched pentasaccharide of ganglioside GM1 [15].
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Results 
Four first-generation inhibitors of receptor binding derived
from galactose are shown in Table 1. We attempted to co-
crystallize each of the four compounds with LT AB5 holo-
toxin under conditions equivalent to those used in the
crystallization of the previously studied LT–galactose
complex [14]. As it happened, however, only the LT–
lactulose complex yielded crystals isomorphous to those of
the LT–galactose complex. Furthermore, the attempted
co-crystallization of holotoxin with thiodigalactoside (TDG)
and with metanitrophenyl-galactoside (MNPG) produced
crystals containing only the toxin B pentamer rather than
the AB5 holotoxin. Dissociation of the A subunit from
the holotoxin during crystallization has been observed
previously, particularly in the presence of divalent cations
[18], but was not expected under these conditions.
Receptor-binding by LT is solely mediated by the B
pentamer, and it is not dependent on the presence or
absence of the A subunit. It is possible that the variable
dissociation of the holotoxin during crystallization was
due in part to our use of engineered variants of the A
subunit (see Materials and methods section), but this
should have no bearing on our investigation of receptor-
binding inhibitors. Regardless of this variability of crystal
growth, clear electron density corresponding to the bound
compound is visible at the receptor-binding site in each
of these four first-generation toxin–inhibitor complexes
(Figures 2 and 3).
Complexes of LTB with thiodigalactoside and 
metanitrophenyl-galactoside
Crystals of these two LTB complexes diffracted to better
than 2 Å resolution. In both complexes, all five receptor-
binding sites on each toxin pentamer are occupied by the
respective galactose derivatives. Electron density for the
bound compound was in each case very clear (Figures 2a
and b) and modeling of the sugar conformations was
straightforward. The protein surface that is buried upon
binding TDG or MNPG is substantially greater than that
buried by the binding of galactose alone, but only half
that buried by the binding of the GM1 pentasaccharide
(Tables 1 and 2). 
Crystals of the LTB–MNPG complex contain two toxin
pentamers per asymmetric unit, affording a view of ten
crystallographically independent copies of the receptor-
binding site. There is a remarkable agreement in the con-
formation of the inhibitor in these independently refined
sites, as well as excellent replication of the local ordered
solvent molecules (Figure 4). After superposition of the
ten sites by least-squares minimization of all protein atoms
within 12 Å of the MNPG molecule bound to each
subunit, the root mean square (rms) deviation from the
average position of corresponding atoms in the ten bound
MNPG molecules is 0.30 Å. Superimposition of the galac-
tose moiety from the averaged MNPG-binding site coordi-
nates back onto galactose itself, as seen in the LT–galactose
crystal structure [14], gives an rms difference of 0.67 Å. 
A similar calculation for the five crystallographically inde-
pendent copies of the binding site in the LTB–TDG
complex also shows an excellent reproducibility in the
observed conformation of the inhibitor and discretely
ordered solvent molecules.
The primary hydrophobic interaction of galactose with
the toxin, the stacking of the galactose pyranose ring over
the indole ring of Trp88, is maintained in all of the com-
plexes reported here. The hydrophobic packing of the
galactose C6 atom against the imidazole ring of His57 is
also conserved. The α-linked nitrophenyl substituent of
MNPG increases the area of hydrophobic contact with the
toxin, extending the interaction surface with Trp88, and is
positioned so that it lies against the sidechain of Tyr12
(Figure 4). The primary atoms involved in these interac-
tions are MNPG C2′, which sits over the Trp88 ring, and
C3′, which lies against the Tyr12 ring.
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Table 1
Comparison of observed binding surface area and inhibition constants.
Galactose derivative Systematic name Buried surface (Å2)* IC50 (mM)†
Galactose β-D-galactopyranose 156(8) 40
Lactulose 4-O–D-galactopyranosyl-D-fructose 195(12) 15
Melibionic acid 6-O–D-galactopyranosyl-D-gluconic acid 232 6
TDG D-galactopyranosyl β-D-thio-galactopyranoside 227(9) 2
MNPG Meta-nitrophenyl–D-galactopyranoside 227(13) 0.5
Ganglioside GM1 Gal(β1–3)GalNAc(β1–4) {NeuAc(α2–3)} Gal(β1–4)Glc(β1–1) 403(10) 0.005
pentasaccharide
*The standard deviation values for buried surface area, given in
parentheses, were calculated from the observed variance in multiple,
crystallographically independent, copies of the binding site in the
crystal structures. Because the conformation of melibionic acid was
completely modeled in only three of 15 independent copies, there
was insufficient accuracy to estimate a standard deviation. †The IC50
values were measured by competitive ELISA and represent the
concentration required to reduce LT holotoxin binding (0.2 µg/ml) to
ganglioside GD1b by 50% (W Minke and C Verlinde, personal
communication). The intrinsic KD of the GM1 pentasaccharide binding
to cholera toxin is 1 µM [42].
As discussed later, the ordered water molecules at the
receptor-binding site in the LTB–MNPG and LTB–TDG
complexes closely parallel the solvent sites seen in the
complex of the cholera toxin B pentamer with the full-
receptor oligosaccharide. The conserved hydrogen-bond-
ing network at the binding site analyzed in previous
toxin–sugar complexes [12,14] is largely maintained for
both MNPG and TDG (Figures 4a and 5). A notable
exception, however, is that in the case of MNPG one
solvent site is occupied instead by the O2′ atom of the
nitrophenyl group (Figure 6). This one-for-one replace-
ment of a substituent oxygen for a tightly associated
water molecule may well contribute substantially to the
favorable IC50 observed for MNPG relative to the other
compounds (Table 1). Hydrogen-bonding interactions of
the displaced water at consensus site #2 are assumed by
the O2′ atom of the inhibitor (Figures 4a and 6). Thus,
O2′ is hydrogen bonded to the backbone amide N atom
of Gly33 and to the water molecule at consensus solvent
site #5. It does not, however, form an internal hydrogen
bond to the galactose O6 hydroxyl group, an interaction
that would be equivalent to that observed when a water
molecule occupies this site.
The second galactose moiety of TDG extends along the
receptor-binding surface in the same general direction as
the nitrophenyl group of MNPG (Figure 6). In doing so,
its C6′ atom extends far enough to gain a hydrophobic
interaction with Tyr12 (Figure 5), although the gain in
hydrophobic-interaction surface is less than for MNPG.
The second sugar of TDG offers more hydrogen-bonding
partners than does the nitrophenyl group of MNPG. Parts
of the solvent-mediated hydrogen-bonding network previ-
ously seen in the full CTB–GM1 pentasaccharide complex
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Figure 2
Electron density at a representative sugar-
binding site in the LTB–TDG and LTB–MNPG
complexes. In each stereo pair, a single sugar-
binding site from the set of non-
crystallographic symmetry equivalents is
shown for one of the two complexes. Sugar
derivative and nearby solvent atoms were
omitted from Fc in calculating difference
density. (a) Fo–Fc difference density map with
superimposed final model for
thiodigalactoside (TDG). Density is contoured
at 3σ. (b) Fo–Fc difference density map with
superimposed final model for meta-nitrophenyl
galactoside (MNPG). Density is contoured at
3σ. (Figures were produced using XtalView
[35] and Raster3D [39].)
[12] are mimicked in the LTB–TDG complex. The water
molecule at consensus site #2 is observed to bridge the
backbone amide of Gly33 and the O6′ atom of TDG. The
TDG O6′ atom thereby substitutes for the role played by
the O8 atom of sialic acid in GM1. The water molecule at
consensus site #3 also is hydrogen bonded to O6′ of TDG,
whereas it is a hydrogen-bond donor to O1A of the sialic
acid in the CTB–GM1-OS complex.
LT–lactulose complex
Lactulose exists as mixture of conformers, both in solution
and in the solid state, due to mutarotation of the fructose
moiety. In the solid state, this mixture normally cor-
responds to a ratio of 75:10:15 for the β-furanose, α-fura-
nose and β-pyranose forms, respectively [19], although the
crystalline trihydrate state adopts purely the β-furanose
form [20]. In the 2.65 Å resolution LT–lactulose complex
reported here, the observed electron density is consistent
with binding of the β-furanose anomer. At the clearest of
the sites (Figure 3a) the observed density provides direct
evidence for two bulky ring substituents, corresponding
to a furanose form and for the β-anomer at the C2 atom.
Density at the remaining crystallographically indepen-
dent sites is consistent with the β-furanose conformer,
but is not so clearly inconsistent with a pyranose or α-
furanose form.
The fructofuranose moiety of lactulose does not contribute
any additional hydrophobic interactions to toxin–lactulose
binding. The consensus solvent-mediated hydrogen-bond-
ing network at the receptor-binding site adjusts, however,
to allow additional hydrogen-bonding interactions involv-
ing the fructose (Figure 7). The water molecule at site #1
forms hydrogens bonds such that it bridges the Asn14
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Figure 3
Stereo views of the electron density at a
representative sugar-binding site in the
LT–lactulose and LT–melibionic acid
complexes. In each stereo pair, a single sugar-
binding site from the set of non-
crystallographic symmetry equivalents is
shown for one of the two complexes. Sugar
derivative and nearby solvent atoms were
omitted from Fc in calculating difference
density. (a) Fo–Fc difference density map with
superimposed final model for lactulose
modeled as galactosyl-D–fructofuranoside.
Density is contoured at 2.5σ to emphasize the
lobe of density at the upper left, which
corresponds to the C1 and O1 atoms of
fructose in the β-furanose anomer. (b)
SigmaA-weighted difference density
contoured at 1.5σ, with superimposed model
for melibionic acid. No discrete solvent sites
have been modeled in this complex. At 2.8 Å,
the resolution is insufficient to model the
precise conformation or specific interactions
of the extended gluconate chain with any
confidence. As shown here, however, the
density envelope is sufficiently clear at three
of the fifteen crystallographically independent
binding sites to indicate the region of the
extended binding site occupied by the full
melibionic acid. (Figures were produced using
XtalView [35] and Raster3D [39].)
sidechain to both O2 of the galactose moiety and O6′ of
the fructose moiety. The water at site #5 shifts slightly to
bridge toxin residues Gln51 and Gln61 to the lactulose O3′.
This increases the distance from this water to the galactose
O6 atom to greater than 3.1 Å, weakening or removing the
water–O6 hydrogen bond found in the canonical toxin–
galactose binding interaction. 
LT–melibionic acid complex
Crystals of the LT–melibionic acid complex exhibited a
superlattice built from multiples of a primitive cell con-
taining a single AB5 holotoxin. Individual crystals of this
complex varied as to the number of primitive cells making
up the predominant repeat unit in the superlattice, and
the underlying disorder limited the effective resolution of
the crystallographic data available for structure determina-
tion. This did not prevent refinement of the toxin B pen-
tamer, which remained well-ordered (see Materials and
methods section). The disaccharide melibionic acid exists
in solution as mixture of conformers, including both the
free acid and aldolactone forms of the gluconic acid residue.
The 2.8 Å resolution view of the bound molecule in the
LT–melibionic acid complex reported here is insufficient
to resolve sugar conformations unambiguously, but sup-
ports a linear (free carboxylic acid) conformer of the glu-
conate moiety rather than an aldolactone (Figure 3b). The
galactose residue of melibionic acid is α-anomeric, unlike
the galactose moieties in previously studied complexes of
LT with the disaccharides lactose [13] and Gal–GalNAc
[16]. Because the anomeric carbon atom C1 is the sugar
linkage site, the second sugar in melibionic acid extends
into a different region of the binding site than was seen
in the previous disaccharide structures. It is clear from
the observed electron-density envelope that the gluconate
moiety of melibionic acid extends through the volume of
space that is occupied by the sialic acid moiety of GM1
during normal receptor binding. In doing so, it must dis-
place the water molecule at consensus site #3. It does not
appear, however, that the carboxylate group of the glu-
conic acid is positioned so as to be analogous to the car-
boxylate of the GM1 sialic acid. It seems instead to be
positioned near to the sidechain of Arg13. This association
should contribute a favorable electrostatic interaction in
addition to the hydrophobic-surface interactions between
the gluconic acid and LT residues Tyr12 and Arg13.
Discussion
We have chosen to approach the structure-based design
of a tight-binding inhibitor through an iterative cycle of
crystallographic analysis, consequent design of chemical
modifications and biochemical characterization of the next
generation of candidate inhibitors [21,22]. The starting
point for this cycle may in general be taken from random
screening, from ab initio design or from fragments of the
normal substrate or other known substrate analogues. We
are following all of these avenues in targeting the recep-
tor-binding site in LT and in cholera toxin, but in this
report we focus on the crystallographic analysis of a first
generation of compounds based on a receptor fragment,
galactose, in complex with LT. 
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Table 2
Interaction surfaces.
Contributing Buried surface on protein (Å2)
residue
LT–galactose LT–lactulose LTB–TDG LTB–MNPG LT–melibiose CTB–GM1-OS
Glu11 7 26
Tyr12 22 21 29 45
Arg/His13 2 16 7 8 28 48
Asn14 6 10 8 6 10 13
Glu51 13 13 12 14 15 15
Ser55 2 1 4
Gln56 29 44 44 28 27 45
His57 13 13 14 15 12 14
Ile58 5 6 8 25
Gln61 13 15 14 17 15 18
Trp88 43 44 52 55 52 54
Asn90 18 18 19 18 17 19
Lys91 18 18 16 17 16 18
Gly33* 3 3 9 19 3 21
Lys34* 3 3 23
Arg35* 13
Total per copy 157 195 227 227 232 403
The values listed are averages over multiple crystallographically
independent copies of the receptor-binding site in each complex. The
decrease in accessible-surface area of the protein was calculated in
program MSCON [43], using a probe radius of 1.4 Å, and broken
down by residue. No solvent molecules were included in accessible-
surface area calculations. Protein residues defining the binding surface
are contributed by two adjacent monomers within the B pentamer;
those from the second are indicated by an asterisk.
Galactose is the terminal sugar of the branched pentasac-
charide chain of the toxin’s natural receptor, ganglioside
GM1. Galactose itself binds weakly to the toxin (Table 1),
and the structural characteristics of the galactose-binding
site on LT are known in considerable detail [14]. The
first iteration of the structure-based design cycle, com-
puter modeling and docking simulations based on the
LT–galactose crystal structure identified a series of com-
mercially available galactose derivatives with inhibition
constants up to 100-fold better than that of galactose itself
(C Verlinde and W Minke, personal communication). The
crystal structures reported here for the complexes of LT
with four of these derivatives show that, as expected, the
molecular interactions between the toxin and the galac-
tose moiety are preserved across the series of derivative
compounds. Meanwhile, the various substituents added to
the galactose ring interact favorably with additional regions
of the receptor-binding site (Figure 6).
Comparison to binding of the natural receptor GM1
The B pentamer of LT contains five identical receptor-
binding sites. Each binding site lies at the juncture of two
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Figure 4
Binding interactions in the LTB–MNPG
complex. (a) Schematic of the hydrogen
bonding and non-polar interactions between
MNPG and the receptor-binding site in LT.
Figure composed using program LIGPLOT
[40]. (b) Superposition (stereo pair) of all ten
crystallographically independent copies of the
MNPG-binding site in the crystal structure.
Protein residues are shown from a single
copy, with residues of the primary subunit
defining this binding site shown in red and
residues from the adjacent subunit in orange.
The remaining copies were superimposed by
least-squares minimization of the positions of
all 103 Cα atoms from the primary subunit of
the respective binding sites. For each of the
ten superimposed sites, the MNPG molecule
is shown in black and associated water
molecules in blue. Consensus solvent sites
are numbered as in Merritt et al. [12,14]. Note
that consensus site #2 (visible in Figures 5b
and 6) is occupied by the O2′ atom of the
MNPG molecule. Note also that the cluster of
water molecules at the top center of (b) lies at
the site occupied by the O1B atom of the
GM1 sialic acid residue in the CTB–GM1-OS
complex [12,15].
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adjacent B subunits, although by far the major portion 
of the binding surface is contributed by only one of 
these two subunits. The surface contributed by the primary
subunit is formed by residues Glu11, Tyr12, His/Arg13,
Asn14, Glu51, Ser55, Gln56, His57, Ile58, Gln61, Trp88,
Asn90 and Lys91. The secondary subunit contributes a
smaller portion of the binding surface formed by residues
Gly33, Lys34 and Arg35 [12]. The major hydrophobic-inter-
action surface on the protein is formed by the indole ring of
Trp88, which complements the hydrophobic face of the
receptor’s galactose ring. The involvement of residues from
the 51–60 loop is noteworthy because this loop is only
poorly ordered in the free toxin structure, but upon sugar-
binding is stabilized both by extensive hydrogen bonding to
the sugar hydroxyl groups and by hydrophobic interaction
involving His57 [14]. This stabilization of the 51–60 loop is
seen in all of the complexes presented here.
The branched pentasaccharide of GM1 binds at each of
these sites by an interaction we have described as a ‘two-
fingered grip’, in which the protein is held by the two
branches of the GM1 branched pentasaccharide [15]. The
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Figure 5
Binding interactions in the LTB–TDG
complex. (a) Schematic of the hydrogen-
bonding and non-polar interactions between
TDG and the receptor-binding site in LT.
Figure composed using program LIGPLOT
[40]. (b) Superposition (stereo pair) of all five
crystallographically independent copies of the
TDG-binding site on LTB in the crystal
structure. Protein residues are shown from a
single copy, with residues of the primary
subunit defining this site shown in red and
residues from the adjacent subunit in orange.
The remaining copies were superimposed as
described previously. For each superimposed
site, the TDG molecule is shown in black and
associated water molecules in blue.
Consensus solvent sites are numbered as in
Merritt et al. [12,14].
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‘forefinger’ of this grip, consisting of the galactose-β(1-4)-
N-acetyl-galactosamine disaccharide, is inserted deeply
into a cleft on the protein. The sialic acid ‘thumb’ extends
along the adjacent protein surface. Although the branched
pentasaccharide of GM1 is much larger than any of our first
generation inhibitors, only three of the GM1 sugar residues
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Figure 6
Superposition of five compounds at the
GM1-binding site. The protein residues,
discrete water molecules and galactose
molecule shown in red are taken from the
2.2 Å resolution structure of the LT–galactose
complex [14]. Superposition of the galactose
derivative compounds was performed by
least-squares minimization of the positions of
corresponding Cα atoms in the toxin
monomers which form their respective binding
sites, against those of the monomer shown for
the LT–galactose complex. TDG is shown in
blue, MNPG in yellow, lactulose in cyan and
GM1-OS [12] in purple. In each case, the
discretely ordered solvent molecules
observed in the crystal structures are shown
in corresponding colors. The numbers shown
are those assigned to consensus solvent sites
in previous analyses of the LT–galactose and
CTB–GM1-OS complexes [12,14]. Note in
particular that one oxygen from the nitrophenyl
group of MNPG lies exactly in the position of
consensus solvent site #2. Note also that the
carboxylate oxygen atom O1B of the GM1
saccharide itself displaces a water molecule
present in the complexes with smaller
compounds (just above and to the right of
labeled solvent site #3 in the figure).
Figure 7
Binding interactions in the LT–lactulose
complex. Schematic of the hydrogen-bonding
and non-polar interactions between lactulose
and the receptor-binding site in LT. Figure
composed using program LIGPLOT [40]. 
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Structure
interact directly with the protein. This corresponds to an
interaction surface of about 400 Å2, the largest areas of
which are due to interactions between the toxin and the
terminal sugars of the two branches, galactose and sialic
acid. The best of the present set of inhibitors bury roughly
half that area upon binding, including the region buried
by the shared galactose moiety (Tables 1 and 2).
The galactose moiety of GM1 at the tip of the ‘forefinger’ is
attached to the remainder of the receptor molecule via a
β(1–4) sugar linkage. Other β-linked disaccharides have
previously been observed to mimic the GM1 forefinger in
conformation upon binding to LT [13,16]. Similarly, in the
present LT–lactulose complex we see that the second,
β(1–4) linked, sugar residue of the bound lactulose extends
into the volume corresponding to N-acetyl-galactosamine in
GM1, but adds only about 40 Å2 to the interaction surface
area (Figure 6). 
The remaining three compounds in the present series
are more interesting, in that their non-galactose portions
span the region of the binding site corresponding to the
space between the terminal galactose forefinger and the
sialic acid thumb of GM1 (Figure 6). In the case of the
bound TDG (D-galactosyl–D-galactoside) molecule, this
closer adherence to the molecular surface of the protein
is adopted notwithstanding the presence of the β-anomeric
sugar linkage. In the case of the bound MNPG (meta-
nitrophenyl–D-galactoside) and melibionic acid (6-O-α-
D-galactosyl-D-gluconic acid) molecules, however, the
direction of extension along the protein surface is due to
the presence of the α-anomeric linkage. The gluconate
chain of melibionic acid extends far enough to occupy
some of the volume corresponding to the GM1 sialic acid,
thereby forming both hydrophobic interactions with protein
residues Tyr12 and Arg13 and perhaps mimicking the
electrostatic interactions of the sialic acid carboxylate
group. It is interesting to note that the β-linked analogue
of this sugar, lactobionic acid, has a much higher IC50
than the α-linked melibionic acid (W Minke and C Ver-
linde, personal communication).
The substituents of TDG and MNPG, the two compounds
with the lowest measured IC50, lie more closely against the
protein surface as they extend from the galactose. By doing
so they make a more intimate contact surface with the
sidechains of Trp88 and Tyr12 than does GM1 and they also
gain an increased interaction surface with Gly33 and Lys34
(Table 2). These interactions are shown schematically in
Figures 4a and 5a, and can be seen clearly in Figures 5 and
6. In the case of the bound MNPG molecule, this more inti-
mate association is achieved by displacing a tightly associ-
ated water molecule at consensus solvent site #2. The
observation that inhibitors may be designed which are even
more complementary to the protein surface than the natural
receptor is quite encouraging.
Importance of tightly-associated water molecules
The molecular surface of a protein to which a ligand or
receptor binds is defined not only by the constituent
atoms of the protein, but also by tightly associated water
molecules. Such discrete sites occupied by well-ordered
solvent molecules are a general characteristic of proteins
as observed in solution [23] or in the crystalline state
[24,25]. In a protein–ligand complex, individual discrete
solvent sites may remain in place and fully occupied; they
may become destabilized and thus less favorable relative
to the unbound state, and hence only partially occupied;
or the solvent molecule originally occupying a site may be
displaced altogether by the ligand or by a conformational
shift in the protein. At a minimum, the presence of such
solvent molecules must be taken into consideration during
docking and modeling studies. Failure to include discrete
water molecules at the protein surface during a search for
complementary small molecules can prevent recognition
of potential tight-binding compounds [26] and can prevent
successful computer docking of a compound known to
bind [26]. Automated computer docking of the present
series of compounds into the receptor-binding site of LT
clearly illustrates this problem (W Minke and C Verlinde,
personal communication). 
On the other hand, the displacement of ordered solvent
may be beneficially employed as a design strategy [27–29].
Thus, one or more water molecules observed in a protein–
inhibitor complex may be displaced by modification of
the inhibitor to include an additional rigid substituent
containing suitable hydrogen-bond partners. In a favorable
case, the protein–modified-inhibitor complex maintains
hydrogen bonds which are enthalpically equivalent to
those formerly involving the displaced water and, together
with entropic contributions of desolvation, results in a
lower Ki. That is, solvent displacement is entropically
favored because ∆S is greater than 0 for the transfer of
the ordered water molecule(s) to bulk solvent, whereas
∆S is ∼ 0 for the transfer of additional atoms of the rigid
inhibitor substituent from the bulk solvent to the position
in the complex. ‘Liberation’ of water molecules hydrogen
bonded to the inhibitor prior to formation of the complex
may add a further favorable entropic term to the energet-
ics of complex formation.
In looking closely at solvent structure near the galactose-
binding site, we identified nine consensus solvent sites
in this region on the basis of well-ordered water mol-
ecules observed in multiple crystallographically indepen-
dent copies of the site in two or more refined structures
[12,14]. Some of these, including sites #2 and #3 (Figure 6),
are consistently observed in essentially every copy of the
binding site even in the absence of bound sugars [14].
The binding of the natural receptor GM1 oligosaccharide
displaces water molecules that are seen to be well-ordered
in complexes of the toxin with smaller saccharides. It is
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quite striking that this displacement puts specific hydro-
gen-bond donor or acceptor atoms of the GM1-OS moiety
at the precise former location of the displaced water mol-
ecules (Figures 5 and 6). Thus, the position of the sialic
acid carboxylate atom O1B is nearly identical to that of 
a discrete water site observed in the LT–galactose and
LTB–MNPG complexes. Coincident solvent sites are also
observed at positions equivalent to the N-acetyl-galactos-
amine atoms N2 and O7 (Figures 5 and 6).
The tightest-binding of the present set of compounds,
MNPG, similarly displaces a well-ordered water mol-
ecule seen in the other complexes, including the CTB–
GM1-OS complex. The nitrophenyl O2′ atom is coinci-
dent with the previously characterized consensus solvent
site #2 and plays the same role: this oxygen is a hydrogen-
bond partner for the backbone amide N atom of protein
residue Gly33 and also for the water at consensus solvent
site #5 (Figures 4 and 8). As described above, this results
in an increased interaction surface area between the protein
and the ligand, and displacement of a water molecule by
part of a larger rigid group (in this case the nitrophenyl) is
entropically favorable.
Towards the next generation of candidate inhibitors
The structural analysis of four first generation inhibitor–
toxin complexes reported here corresponds to the com-
pletion of only a single iteration of the inhibitor-design
cycle. Clearly more cycles of this process will be required
before we achieve an inhibitor with Ki in the nanomolar
range, as required to block normal toxin–receptor binding
effectively. The present analysis does, however, provide
clear signposts to guide the path of subsequent design
cycles. It is encouraging that the four galactose derivatives
described here are one third or less the size of the GM1
pentasaccharide, yet their interaction surface upon
binding is half or more that of GM1 (Table 2), including in
the case of the LTB–MNPG complex a portion of the
surface formed by the edge of Tyr12 that GM1 itself does
not rest against (Figure 8). 
Several other well-ordered waters in addition to that dis-
placed by MNPG at consensus site #2 remain as targets for
incremental inhibitor improvement following the solvent
displacement strategy discussed above. It is worth noting
that sites #4 and #5, in particular, were previously observed
to be occupied only in the presence of bound sugar, and
we hypothesized that the corresponding water molecules
became ‘bound’ concomitant with sugar binding [14]. If
this is indeed the case, then these sites are even more
likely to be favorable targets for occupation by polar atoms
of a second-generation inhibitor design. Inhibition would
then involve binding a single, larger, inhibitor molecule
rather than the concomitant binding of a smaller molecule
plus one or more waters.
Although each of the five identical GM1-binding sites on
the toxin is comprised of residues from two adjacent B
subunits, the surface bound by the galactose moiety is
contributed only by one of them (Table 2). This is largely
true also of the surface buried by our first-generation
series of receptor antagonists. In seeking to improve
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Figure 8
Stereo view of the receptor-binding surface
of LT, with MNPG and GM1-OS
superimposed. The molecular surface of LT
is shown in the region of one of the five
identical receptor-binding sites. The
corresponding conformations of bound
MNPG and GM1-OS are superimposed from
the structures of their respective complexes,
as in Figure 6, with MNPG in yellow and
GMI-OS in purple. Ordered water molecules
are colored to indicate which complex their
depicted location corresponds to.
Consensus solvent sites #1, #3 and #5 are
labeled; consensus site #2 is occupied by
the nitrophenyl group of MNPG (just left of
center in the figure). The floor of the binding
site is formed by residues Tyr12 and Trp88
(unlabeled, background of figure). Note that
the large lobe of the protein surface formed
by Arg13 (far right of figure) is the single
region of difference between the receptor-
binding surfaces of LT and CT. That is, the
close association of the proximal glucose
residue of GM1 with the sidechain of Arg13
is presumably a feature of LT–GM1 binding,
but is not seen in the CTB–GM1-OS crystal
structure [12,15], in which the
corresponding CTB residue is His13. (The
molecular surface shown was calculated in
GRASP [41] and rendered in Raster3D
[39].)
antagonist affinity for the toxin, we can target additional
regions of the toxin surface, including both regions already
buried by the natural receptor GM1 and regions not
involved in normal receptor binding. The former category
includes interaction with the binding-site surface formed
by residues Glu11, Tyr12 and Ile58 of the primary toxin
subunit, and residues Lys34* and Arg35* of the adjacent
subunit (Table 2; Figure 8).
We would ideally like to arrive at inhibitors which can block
receptor binding by either LT or CT. It may be wise there-
fore to avoid the design of specific interactions with the
sidechain of residue 13. Specific interactions of an inhibitor
with this residue would plausibly result in differential
affinity for CT and LT, as this is the one residue at the
binding site for which there is sequence variability
[30,31]. Isolates of LT from E. coli strains pathogenic for
humans have variously been found to contain histidine or
arginine at residue 13. CT contains a histidine at residue
13. Porcine isolates of LT such as the one used for the
present work contain arginine at this residue. This issue
of differential affinity is illustrated by one of the com-
pounds in our present series. The postulated favorable
interaction between the gluconate moiety and the side-
chain of Arg13 suggested by the present LTB–meli-
bionic acid complex is consistent with the observation
that melibionic acid has a considerably more favorable
IC50 against LTB than against CTB (W Minke and C
Verlinde, personal communication). Conversely, the region
near Lys34 and Arg35 shared by the receptor-binding
surface of both toxins may gain in importance in the next
generation of inhibitors.
We are fortunate that many of the problems which can
beset the conversion of an effective inhibitor into an effec-
tive drug do not arise in this particular design effort.
Because the toxin–receptor binding interaction occurs on
the exterior surface of cells lining the lumen of the intes-
tine, it is not necessary that a receptor-antagonist be
absorbed into the body, or that it circulate in the blood, or
that it be transported across one or more membranes in
order to act. Hence, we do not face the usual constraints
on maximum size and hydrophobicity that complicate the
development of drugs against intracellular targets.
Biological implications
E. coli heat-labile enterotoxin (LT) is highly homolo-
gous in sequence, structure and function to cholera
toxin (CT). Both toxins assemble as AB5 heterohexa-
mers, with the five identical receptor-binding sites situ-
ated on the B pentamer. Together, the two toxins are
responsible for millions of deaths each year [1]. Both
toxins attack intestinal epithelial cells via specific bind-
ing to the branched pentasaccharide of ganglioside GM1
at the cell surface. A receptor-binding antagonist which
blocked this interaction would potentially constitute a
prophylactic drug, conferring protection both against
the severe effects of cholera and against the milder
traveller’s diarrhoea caused by LT. The toxin–receptor
interaction is a particularly attractive drug-design
target because it is an extracellular event which occurs
in the intestine. This largely removes issues of
absorption and bioavailability that impose constraints
on the design of orally administered drugs against
intracellular targets.
Crystal structures of toxin complexes previously deter-
mined in our laboratory have revealed many details of
the natural toxin–receptor binding interaction in both
LT and CT. We have used these as the starting point
for an iterative process of structure-based inhibitor
design targeting the receptor-binding site. Four deriva-
tives of galactose (D-galactopyranose), members of a
larger series of first-generation receptor antagonists iden-
tified by computer modeling and competitive binding
assays, have been studied crystallographically in complex
with the target toxin LT. This analysis constitutes the
completion of a single cycle of an ongoing iterative
design process. Our crystallographic investigations
reveal the mode of binding to LT for each of the four
inhibitors: melibionic acid at 2.8 Å, lactulose at 2.6 Å,
nitrophenylgalactoside at (MNPG) 2.2 Å, and thiodi-
galactoside (TDG) at 1.7 Å. The number of toxin pen-
tamers per asymmetric unit ranges from one to three in
these structures, providing five to fifteen independent
views of the binding mode of each galactose derivative.
This affords an unusual degree of insight in to the
accuracy and reproducibility of the structure features
observed. As predicted, the bound conformations of
these galactose derivatives preserve the toxin–galactose
interactions previously observed for toxin–sugar com-
plexes, and gain additional favorable interactions from
the added substituents. The members of the present set
of antagonists with the highest affinity for the B pen-
tamer of LT, TDG and MNPG, bury roughly half of
the binding site surface covered by the full receptor
GM1 pentasaccharide, despite being considerably
smaller. A notable feature of the LTB–MNPG
complex is that the inhibitor displaces a well-ordered
water molecule present in all other previous and
current crystal structures of toxin–sugar complexes.
We interpret the favorable IC50 for MNPG as being
due partly to the additional direct antagonist–toxin
interaction surface gained by this displacement, com-
bined with a concomitant gain in entropy. Other well-
ordered water molecules at the receptor-binding site
constitute obvious targets for similar displacement in
subsequent cycles of the iterative structure-based
design cycle. If the gains in binding affinity achieved in
the first cycle can be equalled in subsequent cycles, the
resulting inhibitors should compete well against the
natural receptor for toxin binding. 
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Materials and methods
Protein expression and purification
LT holotoxin was expressed using the pROFIT thermoinducible expres-
sion vector in E. coli strain MC1061 [32]. Cells were collected by cen-
trifugation and lysed by sonication. The purification protocol described
by Uesaka et al. [33] was followed except that the bacterial crude
extracts were subjected to a 30% ammonium sulfate precipitation in
20 mM TRIS-HCl buffer at pH 7.5, prior to affinity chromatography on
immobilized D-galactose.
The LT holotoxin used in this work contained mutations in the A subunit
to be discussed elsewhere, which are not relevant to the current study.
The procedure of Feil et al. [32] was used to introduce the following
oligonucleotide sequences into the expression system:
Ile232Thr/Tyr233His double mutant:
5′-GGTTGACACACATAACAGAA-3′
Insertion C236a:
5′-TTGACATATATAACAGAATTTGTCGGGATGAATTATGAATAAA-3′
Lactulose was co-crystallized with LT holotoxin containing a double
substitution (Ile232Thr and Tyr233His). The remaining three com-
pounds were co-crystallized with LT holotoxin containing a single
residue insertion (Cys236a) near the C terminus of the A subunit. Both
mutants exhibit normal receptor binding as determined by GM1-ELISA
binding assays (data not shown). 
LTB–TDG complex
D-galactopyranosyl-β-D-thiogalactopyranoside (thiodigalactoside, TDG)
was purchased from Sigma. Crystals grew in capillaries over a period
of six weeks at room temperature from an initially three-layered solution.
The top layer consisted of 8 µl of protein solution (LT AB5 holotoxin
with an OD of 9.0 at 280 nm in 100 mM TRIS pH 7.5, 200 mM NaCl,
0.5 mM EDTA and 0.1 mM azide). The middle layer consisted of 5 µl of
200 mM thiodigalactoside (TDG) in 100 mM TRIS pH 7.5. The bottom
layer consisted of 4 µl 42% PEG 6000 in 100 mM TRIS pH 7.5 and
50 mM NaCl. The LT A subunit apparently dissociated from the B pen-
tamer during crystallization, as the unit cell contents in the crystals
were found to consist of a single LT B pentamer with TDG bound at all
five of the sugar-binding sites. 
Crystallographic data were collected from a single crystal using
0.75 Å X-rays from beamline 7A at DESY. Data to 1.7 Å resolution were
processed using programs DENZO/SCALEPACK. The data set was
unfortunately only 80% complete, and we chose to forego the calculation
of Rfree rather than further reduce the completeness of the data used for
structure determination. A starting model was constructed by placing the
LT B pentamer as seen in the LT–galactose complex [14] via molecular
replacement using AMoRe [34]. Slow-cool simulated annealing followed
by standard positional and B-factor refinement in the presence of a
Babinet bulk solvent model yielded R = 0.253. At this point, bound TDG
was modeled at three of the five sites and subject to real-space refine-
ment. Map fitting and real-space refinement for all the structures reported
here were carried out using the graphics program XtalView [35]. Crystal-
lographic refinement was carried out using X-PLOR version 3.1 [36]. An
initial discrete solvent model was built for the LTB–TDG structure, con-
sisting of 269 ordered water molecules remote from the sugar-binding
sites. After continued conventional refinement it was possible to unam-
biguously build a model for TDG at the remaining two binding sites and
to complete the discrete solvent model including identification of ordered
waters in the vicinity of the bound sugars. The final crystallographic resid-
ual was R = 0.172 including a Babinet bulk solvent correction (Table 3).
LTB–MNPG complex
Meta-nitrophenyl–D-galactoside (MNPG) was purchased from Sigma.
Co-crystallization with LT was conducted as described above, except
that capillary layers contained 5 µl, 6 µl and 4 µl volumes of the protein,
sugar and PEG solutions, respectively. The A subunit was again lost
during crystallization, and the resulting crystals contained two B pen-
tamers per asymmetric unit. Crystallographic data were collected using
a Siemens X1000 detector with CuKα radiation from a rotating anode
source and processed using programs XENGEN and MACRO. A
subset comprising 7% of the data was reserved for monitoring Rfree
during refinement. Two copies of the LT B-pentamer from the LT–galac-
tose complex were placed using AMoRe [34], and the initial model
subject to simulated annealing and conventional refinement as
described above to reach a residual R = 0.221 (Rfree = 0.324). Ten mol-
ecules of MNPG were built into excellent electron density (Figure 2b).
Continued conventional refinement including a Babinet bulk solvent
correction and a minimal discrete solvent model yielded a final residual
R = 0.182 (Rfree = 0.273) (Table 3).
LT–melibionic acid complex
Melibionic acid (6-O–D-galactosyl-D-gluconic acid) was purchased
from Sigma. Co-crystallization with LT was conducted as described
above, except that the central layer of the capillary crystallization con-
tained 9 µl of 250 mM melibionic acid in 100 mM TRIS buffer at
pH 7.5. Crystals were found to contain a superlattice built up from vari-
able numbers of a minimal repeat element containing a single AB5 holo-
toxin. Crystallographic data were collected from a series of crystals,
using both rotating anode and synchrotron radiation sources, in an
attempt to find a single sample with a minimal supercell and maximal
ordering of the holotoxin. The best data obtained was from a single
crystal, whose diffraction peaks could be indexed and integrated as
arising from a unit cell comprising three repeats of the supercell
minimal element. Nevertheless, electron density corresponding to the A
subunit of the toxin is well-defined only at low resolution. The long
α helix of the A2 domain can be seen to be multiply represented within
a given AB5 envelope, indicating the presence of a discrete set of alter-
native orientations of the A subunit relative to the B pentamer and to
the unit cell itself. This disorder is possible because the primary lattice
is defined by layers in which B pentamer packs against B pentamer.
The superlattice arises from variable orientation of the A subunit about
the fivefold axis of the pentamer in this crystal form, and the stochastic
distribution of such orderings within individual crystals leads to the vari-
able numbers of primitive elements making up the apparent unit cell in
different crystals. The loose association of the A subunit with the B
pentamer in LT allows considerable flexibility in their relative orientation
[5,37], which may facilitate this variability. Despite this complex disor-
der and the ambiguity of the actual unit cell, it proved relatively straight-
forward to position three copies of the LT holotoxin into the unit cell
using AMoRe. Rigid-body refinement of the 15 B subunits and 3 A sub-
units in this initial model gave a crystallographic residual R = 0.373
(Rfree = 0.397). Attempts to model the density corresponding to the A
subunits as a superposition of five orientations with variable occupancy
were not deemed worthwhile, given the objectives of this study, and
thus the A subunits were omitted from the model during subsequent
refinement stages. The final stages of positional and B-factor refine-
ment imposed 15-fold non-crystallographic symmetry restraints on the
constituent monomers of the three B pentamers, and included a
Babinet bulk solvent model but no discrete waters. Models for the
bound disaccharides were built into SigmaA-weighted difference
density maps at all 15 binding sites [38]. The quality of the density at
these sites was variable. In each site, the position of the galactose was
clear, but only three of the sites showed sufficient additional density to
individually model a specific conformation of the gluconate chain; in the
remaining sites, the gluconate was simply positioned as an idealized
extended chain.
LT–lactulose complex
Lactulose (4-O–D-galactopyranosyl-D-fructose) was purchased from
Sigma. Crystals of LT containing the double mutation Ile232Thr/
Tyr233His in the A subunit grew in capillaries over 3–4 months at room
temperature via liquid diffusion from an initially three-layered solution as
described above. The protein, sugar and PEG layers contained 7 µl,
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5 µl and 5 µl volumes, respectively. The crystals obtained were iso-
morphous to those obtained from co-crystallization of wild-type LT
with galactose [14]. The unit cell contained one AB5 LT holotoxin per
asymmetric unit, with a lactulose molecule bound at each of the five
crystallographically independent sugar-binding sites in the B pen-
tamer (Table 3).
Crystallographic data were collected at room temperature using a
Siemens X1000 multiwire detector with CuKα radiation from a rotating
anode source, and processed using programs XENGEN and MACRO.
A subset comprising 5% of the unique crystallographic data was
reserved for calculation of Rfree during refinement. The initial crystallo-
graphic model consisted of the LT holotoxin as seen in the LT–galac-
tose complex at 2.2 Å resolution [14]. Rigid-body minimization of the
individual toxin subunits, plus calculation of an overall correction to the
average B value, yielded a residual R = 0.252 (Rfree = 0.236). Analysis
of the behavior of Rfree during several attempted refinement procedures
validated the inclusion of an overall anisotropic B correction, a bulk
solvent model and inclusion of the five lactulose molecules. It did not,
however, support general refinement of individual positional and B
parameters (i.e. the model from the higher resolution LT–galactose
structure was better than that obtainable through independent refine-
ment of the present lower resolution structure). A minimal discrete
solvent model was constructed and refined starting from 46 Fo–Fc
density peaks in the immediate region of the five receptor-binding sites.
Modeling and analysis of the effects of the double mutation on the con-
formation of the A subunit will be reported elsewhere. The final crystal-
lographic residual was R = 0.217 (Rfree = 0.209; Table 3).
Accession numbers
Coordinates and structure factors have been deposited with the
Protein Data Bank with access codes 1LT5 and 1LT6.
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